Did You Know...
...that in 1800 ether was first used by partyers as a fun diversion? Sniffing the gas led to hilarious and raucous laughter as people watched each other become more and more intoxicated and silly. Several doctors independently realized the value ether would have to anesthetize surgery patients. Of those who claimed rights to the "discovery," none had a happy ending. One had a seizure and died defending his rights. Another spent his life in an asylum because he had been denied acclaim. A third became addicted to chloroform and, in a New York City jail, he soaked a cloth in the drug, severed an artery and bled to death.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8063054 | Method of treatment of retinal ischemia with diazoxide A composition including diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide) for the treatment and/or prevention of retinal ischemia and of diseases associated with retinal ischemia. The composition can also contain riluzole, a derivative active in ne... | 11/22/2011 |
| 8053407 | Methods of treating neurological conditions with hematopoeitic growth factors The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor. ... | 11/08/2011 |
| 7795316 | Topical ophthalmic compositions containing tobramycin and dexamethasone Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, t... | 09/14/2010 |
| 7432307 | Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex... | 10/07/2008 |
| 7429602 | Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva Treating allergic conjunctivitis by administered aqueous solutions containing epinastine, optionally in the form of its racemate or its enantiomers and optionally, in the form of the pharmacologically acceptable acid addition salts thereof, to the conjunctiva. ... | 09/30/2008 |
| 7429483 | Use of nerve growth factor for the storage, culture or treatment of cornea The nerve growth factor (NGF) is used for the storage of corneas in culture, for the production and the storage in vitro of single cell populations of the corneal morphological and functional unit (i.e. epithelium, stroma/keratocytes and endothelium) and of the conj... | 09/30/2008 |
| 7413759 | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions Methods for enhancing cognitive ability in infants are shown. The methods comprise feeding infants baby-food compositions containing docosahexaenoic acid (DHA) in an amount of at least about 0.5 mg per gram of the composition. Infants fed a composition containing DH... | 08/19/2008 |
| 7364723 | Liquid preparation for contact lenses A highly safe liquid preparation for contact lenses which contains 0.3 to 50 ppm of a polyamine having recurring units of the formula (I): wherein n is 0 or 1, and which has a high antibacterial effect even at low concentra... | 04/29/2008 |
| 7344725 | Use of inorganic nanoparticles to stabilize hydrogen peroxide solutions The use of inorganic nanoparticles to stabilize aqueous hydrogen peroxide solutions is described. The preferred nanoparticles are formed from clays. The use of nanoparticles formed from synthetic smectite clays is particularly preferred. The stabilized hydrogen pero... | 03/18/2008 |
| 7335803 | Methods and compositions for modulating alpha adrenergic receptor activity Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use. ... | 02/26/2008 |
| 7335682 | Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye A pharmaceutical composition for the treatment of immune-related diseases of ocular surface and the anterior segment of the eye. More specifically, the invention relates to a composition comprising tacrolimus in a pharmaceutically acceptable formulation, particularl... | 02/26/2008 |
| 7321000 | Ophthalmic composition containing N-acetyl-cysteine for the treatment of dry-eye syndrome An ophthalmic pharmaceutical composition containing acetylcysteine as the active ingredient having a mucolitic action, suitable for administration in eyedrops, where N-acetyl-cysteine is neutralised with base DEAE-dextrane in order to reach pH levels preferably betw... | 01/22/2008 |
| 7320786 | Photodynamic therapy treatment for eye disease This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing ... | 01/22/2008 |
| 7306802 | Ophthalmic compositions containing a synergistic combination of three polymers Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity. ... | 12/11/2007 |
| 7304171 | Compounds and methods for cytoprotection Compounds, compositions and methods for treating degenerative diseases and disorders are disclosed, the compounds having the following structure (I): including stereoisomers, prodrugs and pharmaceutically accepta... | 12/04/2007 |
| 7297679 | Cyclosporin compositions A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein. ... | 11/20/2007 |
| 7288520 | Cyclosporin compositions A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxide... | 10/30/2007 |
| 7276476 | Cyclosporin compositions A composition comprising from 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil selected from the group consisting of anise oil, clove oil, cassia oil, cinnamon oil, and combinations thereof, wherein said composition is an ophthalmically acceptable emulsi... | 10/02/2007 |
| 7267830 | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision. The dietary supplements of the invention contain cobeadlets comprising vitamin E and carotenoids in the form ... | 09/11/2007 |
| 7268137 | Ocular therapy A method for treating a subject suffering from epiretinal membrane formation or retinal detachment due to epiretinal membrane formation is disclosed. The method comprises administering a compound of the formula: ... | 09/11/2007 |
| 7265098 | Polyacid/polyalkylene oxide gels and methods for their delivery The present invention relates to improved methods for delivering bioadhesive, bioresorbable, anti-adhesion compositions. Antiadhesion compositions can be made of intermacromolecular complexes of carboxyl-containing polysaccharides, polyethers, polyacids, polyalkylen... | 09/04/2007 |
| 7265117 | Topical brimonidine tartrate formulations that lack chlorine dioxide Topical solution compositions of brimonidine tartrate are disclosed. The solution compositions lack an oxidative preservative. ... | 09/04/2007 |
| 7247623 | Method of treating dry eye disease with non-drying antihistamines A method and preparation for reducing dry eye symptoms and promoting tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the eyes of the subject a non-drying antihistamine compound, such as epinastine hydrochlori... | 07/24/2007 |
| 7235556 | Methods of treating dry eye disorders Fused pyridazine derivatives are useful for treating dry eye disorders and other disorders requiring the wetting of the eye. ... | 06/26/2007 |
| 7235535 | Method of enhancing drainage of lacrimal system with purinergic receptor agonists A method and preparation for enhancing drainage of lacrimal system in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), di... | 06/26/2007 |
| 7232568 | Compositions and methods for treating hyperimmune response in the eye The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with other drugs are described. Also disclosed in the invention are m... | 06/19/2007 |
| 7230032 | Calcium blockers to treat proliferative vitreoretinopathy Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy.... | 06/12/2007 |
| 7223737 | Method of treating dry eye disorders using glycosides The topical use of glycosides for the treatment of dry eye disorders is disclosed. ... | 05/29/2007 |
| 7220780 | Naaladase inhibitors for treating retinal disorders and glaucoma The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors. ... | 05/22/2007 |
| 7214379 | Method for the purification of marigold oleoresin Marigold oleoresin having a low viscosity and a high lutein content which can be filled in soft capsules can be obtained according to the method of the present invention, which is characterized by combining a step of subjecting oleoresin to supercritical fluid extra... | 05/08/2007 |
| 7202209 | Cyclosporin compositions A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein. ... | 04/10/2007 |
| 7169767 | Ophthalmic compositions containing galactomannan polymers and borate The present invention is directed to ophthalmic compositions containing a gelling amount of a combination of galactomannan polysaccharides and borates. The compositions gel or partially gel upon administration to the eye. The present invention also discloses methods... | 01/30/2007 |
| 7141266 | Baby-food compositions enhancing visual acuity and methods therefor Baby-food compositions that enhance visual acuity upon feeding to an infant are shown. The compositions contain docosahexaenoic acid (DHA) in an amount of at least about 0.5 mg per gram of the composition. The source of the DHA can be from DHA-enriched coagulated eg... | 11/28/2006 |
| 7129272 | Apoptosis inhibitor Disclosed is a method for treatment of a subject having a disease or condition associated with apoptosis, which comprises administering to the subject an effective amount of a 15-keto-prostaglandin compound represented by the following formula (I): | 10/31/2006 |
| 7122518 | Method for preventing or reducing collateral phototoxic damage to neighboring tissues during photodynamic therapy of a target tissue A method is provided for preventing or reducing the adverse effects of photodynamic therapy such as collateral damage by regulating the localized phototoxicity of an effector photosensitizer molecule. During photodynamic therapy, the activity of the effector photose... | 10/17/2006 |
| 7115667 | Ophthalmic fluid An ophthalmic fluid containing at least one triglyceride, diglyceride, or monoglyceride which is chemically similar or compatible with compounds found naturally in the lipid layer of the tear film of an ocular substrate. Preferably the glycerides are derived from a ... | 10/03/2006 |
| 7115263 | Compositions and methods for treating hyperimmune response in the eye The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with other drugs are described. Also disclosed in the invention are m... | 10/03/2006 |
| 7112588 | Use of proteasome inhibitors to treat dry eye disorders Proteasome inhibitors are useful for treating dry eye disorders and other disorders requiring the wetting of the eye. ... | 09/26/2006 |
| 7109187 | Estrogenic compounds as anti-mitotic agents The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosa... | 09/19/2006 |
| 7105512 | Ophthalmic aqueous pharmaceutical preparation The present invention provides an ophthalmic aqueous pharmaceutical preparation, which is excellent in anti-inflammatory effect, which is less stimulative and which has high safety and excellent storage stability. The ophthalmic aqueous pharmaceutical preparation co... | 09/12/2006 |
